Last updated on May 2017

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Brief description of study

The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).

Detailed Study Description

Subjects will receive sipuleucel-T, and potentially other medications, as part of the clinical trial in which they are concurrently enrolled. For this study, cellular and humoral immune responses will be assessed. No additional study treatments will be conducted beyond what is required for the subject's concurrent clinical trial.

Clinical Study Identifier: NCT01727154

Find a site near you

Start Over

Henry Ford Health System

Detroit, MI United States
  Connect »